H-FABP plays a crucial role in the uptake and oxidation of long-chain fatty acids in cardiac myocytes, with its absence triggering a compensatory increase in glucose oxidation.
No takes yet. Share an insight, caveat, or question.
Should not change clinical practice; leaves open whether H-FABP targeting alters human myocardial substrate use or outcomes.
Schaap et al. (1999) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: